Clinical trial · Interventional
Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic
Comparative Efficacy of Topical Salicylic Acid/Lactic Acid, Intralesional Candida Antigen, and Their Combination in the Treatment of Warts: A Randomized, Assessor-Blinded, Controlled Trial
NCT07329907CI-TRIAL-00120488CA-SA/LAcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective: To compare the efficacy, safety, and recurrence rates of topical salicylic acid/lactic acid (SA/LA) monotherapy (Group A), intralesional Candida antigen (CA) monotherapy (Group B), and their combination (Group C) for the treatment of warts.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Human Papilloma Virus (HPV) | — | UNRESOLVED | — |
| Warts | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Candida Antigen and Salicylic Acid/Lactic Acid | Combination Product | — | UNRESOLVED |
| Candida Antigen Intralesional Injection | Biological | — | UNRESOLVED |
| Salicylic Acid/Lactic Acid Topical Solution | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- topical monotherapy
- description
- Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
- interventionNames
- Drug: Salicylic Acid/Lactic Acid Topical Solution
- type
- ACTIVE_COMPARATOR
- label
- Intralesional Monotherapy
- description
- Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
- interventionNames
- Biological: Candida Antigen Intralesional Injection
- type
- ACTIVE_COMPARATOR
- label
- Combination Therapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Single or multiple warts. 2. Aged 5 to 60 years. 3. Eligible for both topical and intralesional treatments. 4. No prior wart treatment for at least 1 month. Exclusion Criteria: 1. Pregnancy or lactation. 2. Immunosuppression or use of immunosuppressive drugs. 3. Known sensitivity to study ingredients. 4. Systemic/local inflammation or infection. 5. History of bleeding/clotting disorder, or use of anticoagulants/NSAIDs. 6. History of asthma, allergic skin disorders, or convulsions. 7. History of chronic systemic diseases (renal/hepatic failure, cardiovascular disorders).
References
Publications (0)
Data not yet available
No reference posted for this study.